738 related articles for article (PubMed ID: 9610707)
61. [Intraepithelial prostatic neoplasia].
Stepanov VN; Frank GA; Dzhioev RR
Urol Nefrol (Mosk); 1999; (1):16-9. PubMed ID: 11149338
[TBL] [Abstract][Full Text] [Related]
62. Glutathione S-transferase: differential expression of alpha, mu, and pi isoenzymes in benign prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma.
Bostwick DG; Meiers I; Shanks JH
Hum Pathol; 2007 Sep; 38(9):1394-401. PubMed ID: 17555796
[TBL] [Abstract][Full Text] [Related]
63. Differential histochemical peanut agglutinin stain in benign and malignant human prostate tumors: relationship with prostatic specific antigen immunostain and nuclear DNA content.
Janssen T; Petein M; Van Velthoven R; Van Leer P; Fourmarier M; Vanegas JP; Danguy A; Schulman C; Pasteels JL; Kiss R
Hum Pathol; 1996 Dec; 27(12):1341-7. PubMed ID: 8958309
[TBL] [Abstract][Full Text] [Related]
64. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients.
Mazzucchelli R; Montironi R; Santinelli A; Lucarini G; Pugnaloni A; Biagini G
Prostate; 2000 Sep; 45(1):72-9. PubMed ID: 10960845
[TBL] [Abstract][Full Text] [Related]
65. Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high-grade prostatic intraepithelial neoplasia.
Jack GS; Brash AR; Olson SJ; Manning S; Coffey CS; Smith JA; Shappell SB
Hum Pathol; 2000 Sep; 31(9):1146-54. PubMed ID: 11014584
[TBL] [Abstract][Full Text] [Related]
66. [Influence of prostatic intraepithelial neoplasia on blood levels of PSA and free PSA percentage].
Morote J; López M; de Torres IM; de Torres JA
Actas Urol Esp; 1999 Apr; 23(4):342-9. PubMed ID: 10394655
[TBL] [Abstract][Full Text] [Related]
67. Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma.
Chang SS; Reuter VE; Heston WD; Gaudin PB
Urology; 2001 Jun; 57(6):1179-83. PubMed ID: 11377343
[TBL] [Abstract][Full Text] [Related]
68. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
69. Transforming growth factor-beta expression in prostate neoplasia.
Cardillo MR; Petrangeli E; Perracchio L; Salvatori L; Ravenna L; Di Silverio F
Anal Quant Cytol Histol; 2000 Feb; 22(1):1-10. PubMed ID: 10696454
[TBL] [Abstract][Full Text] [Related]
70. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML
Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167
[TBL] [Abstract][Full Text] [Related]
71. The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma.
Qian J; Wollan P; Bostwick DG
Hum Pathol; 1997 Feb; 28(2):143-8. PubMed ID: 9023393
[TBL] [Abstract][Full Text] [Related]
72. Stratified epithelium in prostatic adenocarcinoma: a mimic of high-grade prostatic intraepithelial neoplasia.
Hameed O; Humphrey PA
Mod Pathol; 2006 Jul; 19(7):899-906. PubMed ID: 16607376
[TBL] [Abstract][Full Text] [Related]
73. Expression of ezrin in prostatic intraepithelial neoplasia.
Pang ST; Fang X; Valdman A; Norstedt G; Pousette A; Egevad L; Ekman P
Urology; 2004 Mar; 63(3):609-12. PubMed ID: 15028477
[TBL] [Abstract][Full Text] [Related]
74. Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma: a detailed analysis of radical prostatectomy specimens from a randomized trial.
Bullock MJ; Srigley JR; Klotz LH; Goldenberg SL
Am J Surg Pathol; 2002 Nov; 26(11):1400-13. PubMed ID: 12409716
[TBL] [Abstract][Full Text] [Related]
75. Overexpression of NSAID-activated gene product in prostate cancer.
Iczkowski KA; Pantazis CG
Int J Surg Pathol; 2003 Jul; 11(3):159-66. PubMed ID: 12894347
[TBL] [Abstract][Full Text] [Related]
76. Metallothionein expression in prostatic carcinoma: correlation with Gleason grade, pathologic stage, DNA content and serum level of prostate-specific antigen.
Moussa M; Kloth D; Peers G; Cherian MG; Frei JV; Chin JL
Clin Invest Med; 1997 Dec; 20(6):371-80. PubMed ID: 9413634
[TBL] [Abstract][Full Text] [Related]
77. Cribriform carcinoma of the prostate and cribriform prostatic intraepithelial neoplasia: incidence and clinical implications.
Rubin MA; de La Taille A; Bagiella E; Olsson CA; O'Toole KM
Am J Surg Pathol; 1998 Jul; 22(7):840-8. PubMed ID: 9669346
[TBL] [Abstract][Full Text] [Related]
78. Apoptotic regulators in prostatic intraepithelial neoplasia (PIN): value in prostate cancer detection and prevention.
Zeng L; Kyprianou N
Prostate Cancer Prostatic Dis; 2005; 8(1):7-13. PubMed ID: 15477876
[TBL] [Abstract][Full Text] [Related]
79. Can basal cells be seen in adenocarcinoma of the prostate?: an immunohistochemical study using high molecular weight cytokeratin (clone 34betaE12) antibody.
Oliai BR; Kahane H; Epstein JI
Am J Surg Pathol; 2002 Sep; 26(9):1151-60. PubMed ID: 12218571
[TBL] [Abstract][Full Text] [Related]
80. Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement.
Murphy GP; Holmes EH; Boynton AL; Kenny GM; Ostenson RC; Erickson SJ; Barren RJ
Prostate; 1995 Mar; 26(3):164-8. PubMed ID: 7534919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
